Myles Nickolich is an Oncology physician affiliated with Penn State Milton S. Hershey Medical Center. OpenAlex indexes 45 publications with 414 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
500 University Dr
Mc A410
Hershey, PA 170332360
Telephone
717-531-6585Registry record last updated 1 Aug 2019.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20211 payment
- Servier Pharmaceuticals LLCProgram year20214 payments
- Alexion Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.5%Kinase inhibitor19.2%Imatinib Mesylate41%Sprycel21%Jakafi19%Iclusig11%Bosulif9%Part D<11 patientsBCL-2 Inhibitor9.1%Venclexta100%Part D<11 patients+ 4 more classes in this area
Anti-infectives
17.1%Fluoroquinolone Antibacterial8.3%Levofloxacin100%Part D<11 patientsAzole Antifungal4.2%Posaconazole100%Part D<11 patients+ 2 more classes in this area
Dermatology
14.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.2%Acyclovir100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Half-Dose Post-Transplant Cyclophosphamide Improves Engraftment Timing and T-cell Chimerism Versus Conventional Dosing for GVHD Prophylaxis
Biology of Blood and Marrow Transplantation
2026 - Allogeneic Transplant Strategies Facilitating Donor Chimerism Might Improve Outcomes in Multihit TP53-Mutated AML/MDS
Biology of Blood and Marrow Transplantation
2026 - Impact of lymphopenia and hypogammaglobulinemia on outcomes in neutropenic patients with hematological malignancies
International Journal of Hematology
2025 - Unmasking Orthostatic Hypotension after Cellular Therapy: Risk Factors, Implications, and Clinical Significance.
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Nancy Olsen, MD
Penn State Milton S. Hershey Medical Center
Michael Glantz, MD
Penn State Milton S. Hershey Medical Center
Joel Sorosky, MD
Penn State Milton S. Hershey Medical Center
Shin Mineishi, MD
Penn State Milton S. Hershey Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”